文献速递血管炎

间隔肾活检在ANCA相关性血管炎中的应用价值

Utility of interval kidney biopsy in ANCA-associated vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究在三级转诊中心纳入57例ANCA相关性血管炎(AAV)患者,共进行59次间隔肾活检(中位时间约130天),旨在评估其在判断组织学应答中的价值。结果显示间隔肾活检可发现更少急性病变和更多慢性损伤,并导致75%(44/59)的患者免疫抑制治疗改变,提示其有助于确定治疗反应和后续疾病管理。

要点

  • 间隔肾活检可显示较初始活检更少的急性病变和更多的慢性损伤。
  • 临床怀疑活动性疾病者仅42%经组织学证实,临床判断错误约四分之一。
  • 间隔肾活检使75%(44/59)的患者免疫抑制治疗发生改变。

核心结论

  • 间隔肾活检有助于确定AAV患者的治疗反应和后续疾病管理,可能提供比初始肾活检更好的预后信息。

研究设计与样本

  • 在具有专门血管炎服务的三级转诊中心,识别接受间隔肾活检的AAV患者,间隔肾活检定义为初始活检显示活动性AAV后、为确定诱导免疫抑制后肾脏组织学应答而进行的重复肾活检。
  • 共识别57例AAV患者,进行至少一次间隔肾活检,总计59次间隔活检,中位间隔活检时间约130天。

主要发现

  • 59次间隔活检中,24例(41%)在活检时临床怀疑活动性疾病,但仅42%经组织学证实。
  • 35例(59%)患者处于临床疾病缓解,其中97%的病例临床判断正确。
  • 临床医生的印象在四分之一患者中不正确。
  • 间隔活检时血尿与组织学活动性不相关。
  • 与初始活检相比,间隔活检显示更少的急性病变和更多的慢性损伤。

临床怎么用

  • 间隔肾活检可用于评估AAV患者诱导免疫抑制后的肾脏组织学应答,并指导后续免疫抑制治疗调整。
  • 应考虑将间隔肾活检纳入未来AAV临床试验和治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: ANCA-associated vasculitis (AAV) is a rare autoimmune disorder that commonly involves the kidney. Early identification of kidney involvement, assessing treatment-response and predicting outcome are important clinical challenges. Here, we assessed the potential utility of interval kidney biopsy in AAV. METHODS: In a tertiary referral centre with a dedicated vasculitis service, we identified patients with AAV who had undergone interval kidney biopsy, defined as a repeat kidney biopsy (following an initial biopsy showing active AAV) undertaken to determine the histological response in the kidney following induction immunosuppression. We analysed biochemical, histological and outcome data, including times to kidney failure and death for all patients. RESULTS: We identified 57 patients with AAV who underwent at least one interval kidney biopsy (59 interval biopsies in total; median time to interval biopsy ∼130 days). Of the 59 interval biopsies performed, 24 (41%) patients had clinically suspected active disease at time of biopsy which was confirmed histologically in only 42% of cases; 35 (59%) patients were in clinical disease-remission, and this was correct in 97% of cases. The clinician's impression was incorrect in one in four patients. Hematuria at interval biopsy did not correlate with histological activity. Interval biopsy showed fewer acute lesions and more chronic damage compared with initial biopsy and led to immunosuppressive treatment-change in 75% (44/59) of patients. Clinical risk prediction tools tended to operate better using interval biopsy data. CONCLUSION: Interval kidney biopsy is useful for determining treatment-response and subsequent disease management in AAV. It may provide better prognostic information than initial kidney biopsy and should be considered for inclusion into future clinical trials and treatment protocols for patients with AAV.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chapman GB, Farrah TE, Chapman FA, et al. Utility of interval kidney biopsy in ANCA-associated vasculitis. Rheumatology (Oxford). 2022. PMID: 34505902. doi:10.1093/rheumatology/keab695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。